University of Exeter Medical School

Angus Jones

Angus Jones

Associate Professor/Honorary Consultant Physician

 angus.jones@exeter.ac.uk

 01392 408538

 RILD Building 

 

University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK

Overview

I am a clinician scientist who combines research in diabetes with work as a consultant physician in the Royal Devon University Healthcare NHS Trust. My research interests are in precision approaches to the management of diabetes, with a focus on practical approaches that can impact clinical practice now or in the near future. This includes approaches to improving clinical classification of diabetes, both through optimising use of classification biomarkers such as C-peptide and islet autoantibodies, and through development of prediction models to combine clinical features and biomarkers to guide diabetes classification and treatment. This work has informed national and international guidance in this area. Additional interests include developing stratified approaches to treatment of type 2 diabetes and, as part of my work with the University of Exeter NIHR Global Health Group, approaches to effective diabetes diagnosis, monitoring and classification in low resource settings. My research combines new multi-centre clinical studies with analysis of data from healthcare records, trial and observational studies and I work closely with methodology, laboratory and clinical colleagues, alongside national and international collaborators.

Qualifications

  • 2000 BSc. Clinical and Biological Sciences (1st), University of London (Imperial) 
  • 2001 MBBS, University of London (St. Georges)
  • 2004 MRCP 
  • 2005 DTM&H (Distinction), University of Liverpool
  • 2008 Pg Cert Ed, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth
  • 2014 PhD, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth
  • 2014 MRCP Endocrinology and Diabetes
  • 2016 CCT Endocrinology & General (Internal) Medicine

Back to top

Research

Research interests

Practical C-peptide testing, and its clinical utility

I have worked with colleagues in Exeter to develop practical inexpensive approaches to measuring insulin secretion using a test called C-peptide, and show that these approaches can be used to assist classification and treatment of diabetes. Our work in this area, together with our related work demonstrating that misclassification of diabetes is common, has contributed to the widespread up-take of C-peptide testing in clinical care to confirm diabetes subtype and treatment requirements.

Accurate classification of diabetes

Our research has shown that misclassification of diabetes is common, and that simple cut offs, such as those suggested by current guidelines, perform poorly. To address we have developed clinical prediction models to allow clinicians to integrate different clinical features and biomarkers to accurately differentiate type 1 and 2 diabetes, validating them in multiple circumstances and populations, including leading ongoing prospective studies across 55 NHS Trusts. This work has contributed to recent guideline changes to recommend routine islet-autoantibody testing in suspected type 1 diabetes in adults, with reconsideration of the diagnosis and subsequent C-peptide testing where this test is negative. Related work has demonstrated that reported changes in type 1 diabetes with older age, including a milder overlapping form of diabetes termed ‘Latent Autoimmune Diabetes in Adults’, may be explained by issues related to classification and diagnostic test interpretation. We have shown that when these issues are addressed the characteristics of type 1 (autoimmune) diabetes in older adults remains remarkably similar to the young.

Optimising individual’s treatment response in type 2 diabetes

I lead and support work using existing electronic healthcare record and trial data, and new multicenter studies, to stratify treatment in type 2 diabetes. This has led to a number of important findings on targeting diabetes treatment, using simple clinical features, classification tests and genetic markers.

Diabetes in Sub-Saharan Africa

I am Director (with Co-Director Professor Moffat Nyirenda, MRC/UVRI/LSHTM Uganda Research Unit) of an NIHR Global Health Group studying diabetes in Sub-Saharan Africa, and was acting Co-Director of our previous group. In this role I work closely with investigators in Sub-Saharan Africa to understand the optimal approach to diagnosing, preventing and treating diabetes in the Sub-Saharan African setting.

Research projects

Current:​

  • Evaluating the feasibility of remote C-peptide testing for confirming established type 1 diabetes in clinical practice. MRC IAA Impact Visionary Fund, co-investigator.
  • Assessing endogenous insulin secretion in UK biobank to improve diabetes classification and treatment. Diabetes UK, lead investigator.
  • Understanding the aetiology of youth onset type 1 diabetes in Sub-Saharan-Africa. NIHR Exeter BRC, Co-lead investigator.
  • Precision treatment of type 2 diabetes: understanding biomarker predictors of differential response to oral glucose lowering therapies in the TRIMASTER crossover trial. Novo Nordisk Foundation (Denmark), lead investigator.
  • Developing clinical calculators to improve classification of atypical diabetes and diabetes in under-represented populations. Diabetes UK, co-investigator.
  • Using genetics to better diagnose and treat adult-onset T1D in multi-ethnic US population. JDRF USA, Co-Investigator.
  • Developing a decision support tool to enable precision treatment of type 2 diabetes. Medical Research Council, Co-investigator.
  • Combining clinical features and biomarkers to identify patients with Type 1 diabetes in later life (StartRight Prime). Diabetes UK, lead Investigator.

Previous:

  • NIHR Global Health Research Group at the University of Exeter: Improving outcomes in sub-saharan african diabetes through better diagnosis and treatment (acting Co-Director and Research Lead)
  • StartRight (NIHR Clinican Scientist Award, Lead Investigator) - Getting the right classification and treatment from diagnosis in young adults with diabetes
  • Defining the decline in endogenous insulin secretion in Type 1 diabetes diagnosed after 30 years of age (DROPLeT) (JDRF, Joint Lead Investigator).
  • Using a genetic risk score to identify patients with type 1 diabetes who will require early insulin therapy (EFSD Rising Star Fellowship, Lead Investigator)
  • Predicting Response to Incretin Based Agents (PRIBA) (NIHR Doctoral Research Fellowship, Lead Investigator) - Identifying clinical and biomarker predictors of response to incretin based therapies for type 2 diabetes
  • GREAT (NIHR Exeter Clinical Research Facility/Northcott Devon Foundation, Co-lead investigator) - C-peptide and hypoglcyaemia risk in Type 2 diabetes
  • DIRECT (EU IMI) - Stratification of treatment response and progression in Type 2 diabetes

Back to top

Publications

Journal articles

Dennis J, Jones A, Shields B, Hattersley A (In Press). Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. BMC Medical Informatics and Decision Making Abstract.
Jones AG, Shields BM, Oram RA, Dabelea DM, Hagopian WA, Lustigova E, Shah AS, Knupp J, Mottl AK, D’Agostino RB, et al (2024). Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: the SEARCH for Diabetes in Youth Study. Diabetes Care Abstract.
Thomas NJ, Jones AG (2024). Comments on the notion of false positivity in measurements of autoantibodies. Reply to Grill V, Sørgjerd E, Hals I, Carlsson S [letter]. Diabetologia, 67(3), 569-570.  Author URL.
Kirolos A, Harawa PP, Chimowa T, Divala O, Freyne B, Jones AG, Lelijveld N, Lissauer S, Maleta K, Gladstone MJ, et al (2024). Long-term outcomes after severe childhood malnutrition in adolescents in Malawi (LOSCM): a prospective observational cohort study. The Lancet Child & Adolescent Health, 8(4), 280-289.
Venkatesan U, Amutha A, Jones AG, Shields BM, Anjana RM, Unnikrishnan R, Mappillairajan B, Mohan V (2024). Performance of European prediction models for classification of type 1 and type 2 diabetes in Indians. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 103007-103007.
Thomas NJ, Hill AV, Dayan CM, Oram RA, McDonald TJ, Shields BM, Jones AG, StartRight Study Group (2023). Age of Diagnosis Does Not Alter the Presentation or Progression of Robustly Defined Adult-Onset Type 1 Diabetes. Diabetes Care, 46(6), 1156-1163. Abstract.  Author URL.
Allesøe RL, Lundgaard AT, Hernández Medina R, Aguayo-Orozco A, Johansen J, Nissen JN, Brorsson C, Mazzoni G, Niu L, Biel JH, et al (2023). Author Correction: Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models. Nat Biotechnol, 41(7).  Author URL.
Allesøe RL, Lundgaard AT, Hernández Medina R, Aguayo-Orozco A, Johansen J, Nissen JN, Brorsson C, Mazzoni G, Niu L, Biel JH, et al (2023). Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models. Nature Biotechnology, 41(3), 399-408. Abstract.
Brown AA, Fernandez-Tajes JJ, Hong M-G, Brorsson CA, Koivula RW, Davtian D, Dupuis T, Sartori A, Michalettou T-D, Forgie IM, et al (2023). Genetic analysis of blood molecular phenotypes reveals common properties in the regulatory networks affecting complex traits. Nature Communications, 14(1).
Young KG, McGovern AP, Barroso I, Hattersley AT, Jones AG, Shields BM, Thomas NJ, Dennis JM (2023). HbA1c screening for the diagnosis of diabetes. Reply to Brož J, Brabec M, Krollová P et al [letter]. Diabetologia, 66(8), 1578-1579.  Author URL.
Thomas NJ, McGovern A, Young KG, Sharp SA, Weedon MN, Hattersley AT, Dennis J, Jones AG (2023). Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches. J Clin Epidemiol, 153, 34-44. Abstract.  Author URL.
Dawed AY, Mari A, Brown A, McDonald TJ, Li L, Wang S, Hong M-G, Sharma S, Robertson NR, Mahajan A, et al (2023). Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. The Lancet Diabetes & Endocrinology, 11(1), 33-41.
Cardoso P, Young KG, Nair ATN, Hopkins R, McGovern AP, Haider E, Karunaratne P, Donnelly L, Mateen BA, Sattar N, et al (2023). Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Abstract.
Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, Clark AL, Colclough K, Corcoy R, Cromer SJ, et al (2023). Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nature Medicine, 29(10), 2438-2457.
Thomas NJ, Jones AG (2023). The challenges of identifying and studying type 1 diabetes in adults. Diabetologia, 66(12), 2200-2212. Abstract.  Author URL.
Katte JC, McDonald TJ, Sobngwi E, Jones AG (2023). The phenotype of type 1 diabetes in sub-Saharan Africa. Frontiers in Public Health, 11 Abstract.
Young KG, McInnes EH, Massey RJ, Kahkoska AR, Pilla SJ, Raghavan S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, et al (2023). Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review. Commun Med (Lond), 3(1). Abstract.  Author URL.
Niwaha AJ, Rodgers LR, Carr ALJ, Balungi PA, Mwebaze R, Hattersley AT, Shields BM, Nyirenda MJ, Jones AG (2022). Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study. BMJ Open Diabetes Res Care, 10(2). Abstract.  Author URL.
Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, et al (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health, 4(12), e873-e883. Abstract.  Author URL.
Tatovic D, Jones AG, Evans C, Long AE, Gillespie K, Besser REJ, Leslie RD, Dayan CM (2022). Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium. Diabetic Medicine, 39(7).
Wesolowska-Andersen A, Brorsson CA, Bizzotto R, Mari A, Tura A, Koivula R, Mahajan A, Vinuela A, Tajes JF, Sharma S, et al (2022). Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: an IMI DIRECT study. Cell Reports Medicine, 3(1), 100477-100477.
Garbutt J, England C, Jones AG, Andrews RC, Salway R, Johnson L (2022). Is glycaemic control associated with dietary patterns independent of weight change in people newly diagnosed with type 2 diabetes? Prospective analysis of the Early-ACTivity-In-Diabetes trial. BMC Medicine, 20(1). Abstract.
Grace SL, Bowden J, Walkey HC, Kaur A, Misra S, Shields BM, McKinley TJ, Oliver NS, McDonald TJ, Johnston DG, et al (2022). Islet Autoantibody Level Distribution in Type 1 Diabetes and Their Association with Genetic and Clinical Characteristics. J Clin Endocrinol Metab, 107(12), e4341-e4349. Abstract.  Author URL.
Kibirige D, Sekitoleko I, Balungi P, Kyosiimire-Lugemwa J, Lumu W, Jones AG, Hattersley AT, Smeeth L, Nyirenda MJ (2022). Islet autoantibody positivity in an adult population with recently diagnosed diabetes in Uganda. PLOS ONE, 17(5), e0268783-e0268783. Abstract.
JC K, G L, MY D, AG J, TJ M, E S, JC M (2022). Mortality amongst children and adolescents with type 1 diabetes in sub-Saharan Africa: the case study of the changing diabetes in children program in Cameroon.
Shields BM, Angwin CD, Shepherd MH, Britten N, Jones AG, Sattar N, Holman R, Pearson ER, Hattersley AT (2022). Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study. Nature Medicine, 29(2), 384-391.
Shields BM, Dennis JM, Angwin CD, Warren F, Henley WE, Farmer AJ, Sattar N, Holman RR, Jones AG, Pearson ER, et al (2022). Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. Nature Medicine, 29(2), 376-383.
Eason RJ, Thomas NJ, Hill AV, Knight BA, Carr A, Hattersley AT, McDonald TJ, Shields BM, Jones AG, StartRight Study Group, et al (2022). Routine Islet Autoantibody Testing in Clinically Diagnosed Adult-Onset Type 1 Diabetes can Help Identify Misclassification and the Possibility of Successful Insulin Cessation. Diabetes Care, 45(12), 2844-2851. Abstract.  Author URL.
Jones AG, Eichmann M (2022). T-Cell Autoreactivity in Type 2 Diabetes: Benign or Pathogenic, Smoke or Fire?. Diabetes, 71(6), 1167-1169.
Young KG, McGovern AP, Barroso I, Hattersley AT, Jones AG, Shields BM, Thomas NJ, Dennis JM (2022). The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis. Diabetologia, 66(2), 300-309. Abstract.
Kibirige D, Sekitoleko I, Lumu W, Jones AG, Hattersley AT, Smeeth L, Nyirenda MJ (2022). Understanding the pathogenesis of lean non-autoimmune diabetes in an African population with newly diagnosed diabetes. Diabetologia, 65(4), 675-683. Abstract.
Leslie RD, Evans-Molina C, Freund-Brown J, Buzzetti R, Dabelea D, Gillespie KM, Goland R, Jones AG, Kacher M, Phillips LS, et al (2021). Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. Diabetes Care, 44(11), 2449-2456. Abstract.
Greiner R, Nyrienda M, Rodgers L, Asiki G, Banda L, Shields B, Hattersley A, Crampin A, Newton R, Jones A, et al (2021). Associations between low HDL, sex and cardiovascular risk markers are substantially different in sub-Saharan Africa and the UK: analysis of four population studies. BMJ Glob Health, 6(5). Abstract.  Author URL.
Rodgers LR, Hill AV, Dennis JM, Craig Z, May B, Hattersley AT, McDonald TJ, Andrews RC, Jones A, Shields BM, et al (2021). Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study. BMC Medicine, 19(1). Abstract.
Niwaha AJ, Rodgers LR, Greiner R, Balungi PA, Mwebaze R, McDonald TJ, Hattersley AT, Shields BM, Nyirenda MJ, Jones AG, et al (2021). HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study. BMJ Open Diabetes Research & Care, 9(1), e002350-e002350. Abstract.
Jones AG, McDonald TJ, Shields BM, Hagopian W, Hattersley AT (2021). Latent Autoimmune Diabetes of Adults (LADA) is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care, 44(6), 1243-1251. Abstract.
Katte JC, Lemdjo G, Dehayem MY, Jones AG, McDonald TJ, Sobngwi E, Mbanya JC (2021). Mortality amongst children and adolescents with type 1 diabetes in. <scp>sub‐Saharan</scp>. Africa: the case study of the Changing Diabetes in Children program in Cameroon. Pediatric Diabetes, 23(1), 33-37.
Bizzotto R, Jennison C, Jones AG, Kurbasic A, Tura A, Kennedy G, Bell JD, Thomas EL, Frost G, Eriksen R, et al (2021). Processes Underlying Glycemic Deterioration in Type 2 Diabetes: an IMI DIRECT Study. Diabetes Care, 44(2), 511-518. Abstract.  Author URL.
Grace SL, Cooper A, Jones AG, McDonald TJ (2021). Zinc transporter 8 autoantibody testing requires age-related cut-offs. BMJ Open Diabetes Res Care, 9(1). Abstract.  Author URL.
Bar N, Korem T, Weissbrod O, Zeevi D, Rothschild D, Leviatan S, Kosower N, Lotan-Pompan M, Weinberger A, Le Roy CI, et al (2020). A reference map of potential determinants for the human serum metabolome. Nature, 588(7836), 135-140. Abstract.
Milln JM, Walugembe E, Ssentayi S, Nkabura H, Jones AG, Nyirenda MJ (2020). Comparison of oral glucose tolerance test and ambulatory glycaemic profiles in pregnant women in Uganda with gestational diabetes using the FreeStyle Libre flash glucose monitoring system. BMC Pregnancy and Childbirth, 20(1). Abstract.
Eriksen R, Perez IG, Posma JM, Haid M, Sharma S, Prehn C, Thomas LE, Koivula RW, Bizzotto R, Prehn C, et al (2020). Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: an IMI DIRECT study. EBioMedicine, 58, 102932-102932.
Carr ALJ, Perry DJ, Lynam AL, Chamala S, Flaxman CS, Sharp SA, Ferrat LA, Jones AG, Beery ML, Jacobsen LM, et al (2020). Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes. Diabetic Medicine, 37(12), 2160-2168. Abstract.
Lynam AL, Dennis JM, Owen KR, Oram RA, Jones AG, Shields BM, Ferrat LA (2020). Logistic regression has similar performance to optimised machine learning algorithms in a clinical setting: application to the discrimination between type 1 and type 2 diabetes in young adults. Diagnostic and Prognostic Research, 4(1). Abstract.
Katte J-C, Poka-Mayap V, Niwaha A, Nakanga W, Jones A, McDonald TJ, Sobgnwi E (2020). Post-meal Urinary C-peptide creatinine ratio is a moderate measure of insulin secretion in diabetes patients in Cameroon: results from a cross-sectional study. PAMJ Clinical Medicine, 3
Atabaki-Pasdar N, Ohlsson M, Viñuela A, Frau F, Pomares-Millan H, Haid M, Jones AG, Thomas EL, Koivula RW, Kurbasic A, et al (2020). Predicting and elucidating the etiology of fatty liver disease: a machine learning modeling and validation study in the IMI DIRECT cohorts. PLOS Medicine, 17(6), e1003149-e1003149.
Agbaje OF, Coleman RL, Hattersley AT, Jones AG, Pearson ER, Shields BM, Holman RR (2020). Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus – a MASTERMIND precision medicine approach (UKPDS 87). Diabetes Research and Clinical Practice, 166, 108333-108333.
McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Dennis JM (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research & Care, 8(1), e001238-e001238. Abstract.
Jones AG, Shields BM, Dennis JM, Hattersley AT, McDonald TJ, Thomas NJ (2020). The challenge of diagnosing type 1 diabetes in older adults. Diabet Med, 37(10), 1781-1782.  Author URL.
Angwin C, Jenkinson C, Jones A, Jennison C, Henley W, Farmer A, Sattar N, Holman RR, Pearson E, Shields B, et al (2020). TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. BMJ Open, 10(12), e042784-e042784. Abstract.
Gudmundsdottir V, Pedersen HK, Mazzoni G, Allin KH, Artati A, Beulens JW, Banasik K, Brorsson C, Cederberg H, Chabanova E, et al (2020). Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. Genome Medicine, 12(1). Abstract.
Grubb AL, McDonald TJ, Rutters F, Donnelly LA, Hattersley AT, Oram RA, Palmer CNA, van der Heijden AA, Carr F, Elders PJM, et al (2019). A Type 1 Diabetes Genetic Risk Score can Identify Patients with GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. DIABETES CARE, 42(2), 208-214.  Author URL.
Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019). Clusters provide a better holistic view of type 2 diabetes than simple clinical features - Authors' reply. Lancet Diabetes Endocrinol, 7(9).  Author URL.
Lynam A, McDonald T, Hill A, Dennis J, Oram R, Pearson E, Weedon M, Hattersley A, Owen K, Shields B, et al (2019). Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years. BMJ Open, 9(9). Abstract.  Author URL.
Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019). Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol, 7(6), 442-451. Abstract.  Author URL.
Wilman HR, Parisinos CA, Atabaki-Pasdar N, Kelly M, Thomas EL, Neubauer S, Jennison C, Ehrhardt B, Baum P, Schoelsch C, et al (2019). Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. Journal of Hepatology, 71(3), 594-602. Abstract.
Marren SM, Hammersley S, McDonald TJ, Shields BM, Knight BA, Hill A, Bolt R, Tree TI, Roep BO, Hattersley AT, et al (2019). Persistent C-peptide is associated with reduced hypoglycaemia but not HbA1c in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabet Med, 36(9), 1092-1099. Abstract.  Author URL.
Dennis JM, Henley WE, McGovern AP, Farmer AJ, Sattar N, Holman RR, Pearson ER, Hattersley AT, Shields BM, Jones AG, et al (2019). Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: a retrospective analysis of primary care data, 2010-2017. Diabetes Obes Metab, 21(7), 1576-1584. Abstract.  Author URL.
Thomas NJ, Lynam AL, Hill AV, Weedon MN, Shields BM, Oram RA, McDonald TJ, Hattersley AT, Jones AG (2019). Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia, 62(7), 1167-1172. Abstract.  Author URL.
Kibirige D, Lumu W, Jones AG, Smeeth L, Hattersley AT, Nyirenda MJ (2019). Understanding the manifestation of diabetes in sub Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review. Clin Diabetes Endocrinol, 5 Abstract.  Author URL.
Dawed AY, Zhou K, van Leeuwen N, Mahajan A, Robertson N, Koivula R, Elders PJM, Rauh SP, Jones AG, Holl RW, et al (2019). Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i>) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i>) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: an IMI DIRECT Study. DIABETES CARE, 42(6), 1027-1033.  Author URL.
McGovern AP, Dennis JM, Shields BM, Hattersley AT, Pearson ER, Jones AG, MASTERMIND Consortium (2019). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? a MASTERMIND study. BMC Med, 17(1). Abstract.  Author URL.
Jones AG, McDonald TJ (2018). Comment on: “Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, −4 and −5 trials”. Diabetes, Obesity and Metabolism, 20(6), 1549-1550.
Dennis JM, Shields BM, Jones AG, Pearson ER, Hattersley AT, Henley WE, MASTERMIND consortium (2018). Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. Clin Epidemiol, 10, 1869-1877. Abstract.  Author URL.
Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, et al (2018). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated with Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. DIABETES CARE, 41(4), 705-712.  Author URL.
Hope SV, Knight BA, Shields BM, Hill AV, Choudhary P, Strain WD, McDonald TJ, Jones AG (2018). Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 61(1), 66-74. Abstract.
Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, et al (2018). Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: a Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. DIABETES CARE, 41(9), 1844-1853.  Author URL.
Curtis HJ, Dennis JM, Shields BM, Walker AJ, Bacon S, Hattersley AT, Jones AG, Goldacre B (2018). Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes, Obesity and Metabolism, 20(9), 2159-2168. Abstract.
Chakera AJ, McDonald TJ, Knight BA, Vaidya B, Jones AG (2017). Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. Clin Med (Lond), 17(1), 18-21. Abstract.  Author URL.
Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH, Stewart C, Holman RR, et al (2017). Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. DIABETES OBESITY & METABOLISM, 19(3), 356-363.  Author URL.
Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, Hattersley AT, Weedon MN (2016). A Type 1 Diabetes Genetic Risk Score can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 39(3), 337-344. Abstract.  Author URL.
Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, Hattersley AT, PRIBA Study Group (2016). Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care, 39(2), 250-257. Abstract.  Author URL.
Hope SV, Wienand-Barnett S, Shepherd M, King SM, Fox C, Khunti K, Oram RA, Knight BA, Hattersley AT, Jones AG, et al (2016). Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis. Br J Gen Pract, 66(646), e315-e322. Abstract.  Author URL.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016). Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabetic medicine : a journal of the British Diabetic Association, 33(11), 1554-1558. Abstract.
Jones AG, Lonergan M, Henley WE, Pearson ER, Hattersley AT, Shields BM (2016). Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. PLoS One, 11(4). Abstract.  Author URL.
Oram RA, Hill A, Mcdonald TJ, Patel KA, Jones AG, Hattersley AT, Weedon MN (2015). 3. A Novel, Inexpensive Test can Discriminate between Type 1 and Type 2 Diabetes (1745-P). Nederlands Tijdschrift voor Diabetologie, 13(3), 57-57.
Shields BM, Peters JL, Cooper C, Lowe J, Knight BA, Powell RJ, Jones A, Hyde CJ, Hattersley AT (2015). Can clinical features be used to differentiate type 1 from type 2 diabetes? a systematic review of the literature. BMJ Open, 5(11). Abstract.  Author URL.
Jones AG, McDonald TJ, Hattersley AT, Shields BM (2014). Effect of the holiday season in patients with diabetes: Glycemia and lipids increase postholiday, but the effect is small and transient. Diabetes Care, 37(5).
Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, Hattersley AT, McDonald TJ (2014). Erratum to: the majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1).  Author URL.
Jones AG, Shields BM, Hyde CJ, Henley WE, Hattersley AT (2014). Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine. PLoS One, 9(10). Abstract.  Author URL.
Oram RA, Jones AG, Besser REJ, Knight BA, Shields BM, Brown RJ, Hattersley AT, McDonald TJ (2014). The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1), 187-191. Abstract.
Oram RA, Jones AG, Besser REJ, Knight BA, Shields BM, Brown RJ, Hattersley AT, McDonald TJ (2013). Erratum to: the majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 57(1), 262-262.
Jones AG, Knight BA, Baker GC, Hattersley AT (2013). Practical implications of choice of test in National Institute for Health and Clinical Excellence (NICE) guidance for the prevention of Type 2 diabetes. Diabet Med, 30(1), 126-127.  Author URL.
Jones AG, Hattersley AT (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30(7), 803-817. Abstract.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields B, Mcdonald T, Knight BA, Hattersley A (2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine, 30(11), 1342-1348. Abstract.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2013). Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabet Med, 30(11), 1342-1348. Abstract.  Author URL.
Jones AG, Besser REJ, Shields BM, McDonald TJ, Hope SV, Knight BA, Hattersley AT (2012). Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocrine Disorders, 12 Abstract.
Jones AG, Evans PH, Vaidya B (2012). EASILY MISSED? Phaeochromocytoma. BMJ-BRITISH MEDICAL JOURNAL, 344  Author URL.
Jones AG, Evans PH, Vaidya B (2012). Phaeochromocytoma. BMJ, 344  Author URL.
Thomas NJ, Shields BM, Besser REJ, Jones AG, Rawlingson A, Goodchild E, Leighton C, Bowman P, Shepherd M, Knight BA, et al (2012). The impact of gender on urine C-peptide creatinine ratio interpretation. Ann Clin Biochem, 49(Pt 4), 363-368. Abstract.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012). The impact of insulin administration during the mixed meal tolerance test. Diabet Med, 29(10), 1279-1284. Abstract.  Author URL.
McDonald TJ, Perry MH, Jones AG, Donohoe M, Salzmann MB, O'Connor J (2011). A novel case of a raised testosterone and LH in a young man. Clinica Chimica Acta, 412(21-22), 1999-2001. Abstract.
Jones A, Bull M, Vaidya B (2011). A woman with episodic headaches, sweating, and palpitations. BMJ, 342  Author URL.
Jones A, Bull M, Vaidya B (2011). PICTURE QUIZ a woman with episodic headaches, sweating, and palpitations. BRITISH MEDICAL JOURNAL, 342  Author URL.
Besser REJ, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care, 34(3), 607-609. Abstract.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Shields BM, Hope SV, Bowman P, Oram RA, Knight BA, Hattersley AT (2011). Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med, 28(9), 1034-1038. Abstract.  Author URL.
Jones AG, Hattersley AT (2010). Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age. Nat Rev Endocrinol, 6(6), 347-351. Abstract.  Author URL.
Edwards RJ, Taylor GW, Ferguson M, Murray S, Rendell N, Wrigley A, Bai Z, Boyle J, Finney SJ, Jones A, et al (2005). Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J Infect Dis, 192(5), 783-790. Abstract.  Author URL.

Chapters

Jones AG, Vaidya B (2014). Preoperative endocrine function and fluid electrolyte balance. In  (Ed) Pituitary Apoplexy, 95-105. Abstract.
Jones AG, Hattersley AT (2011). Monogenic causes of diabetes. In Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ (Eds.) Textbook of Diabetes, John Wiley & Sons.

Conferences

Simpson VE, Thomas N, Hill AV, Fraser D, Patel K, Shields BM, McDonald T, Jones AG (2023). Antibody-positive patients initially treated as type 2 diabetes who rapidly progress to insulin have similar type 1 and type 2 genetic risk scores and C-peptide loss as patients with type 1 diabetes.  Author URL.
Knupp J, Hill A, McDonald TJ, Thomas N, Oram R, Hattersley AT, McKinley T, Shields BM, Jones AG (2023). Diabetes classification models have high performance when prospectively validated in adults with new onset diabetes.  Author URL.
Katte JC, Dehayem MY, Shields BM, Hattersley AT, Sobngwi E, Jones AG, McDonald TJ (2023). Dried blood spot C-peptide measurements show robust performance in assessing endogenous insulin secretion in individuals with young-onset insulin-treated diabetes.  Author URL.
Katte JC, Sobngwi E, Shields BM, Nyirenda M, Hattersley AT, Jones AG, McDonald TJ (2023). Home-collected dried blood spot C-peptide measurement is a robust measure of assessing endogenous insulin secretion in free-living individuals with young-onset insulin-treated diabetes.  Author URL.
Katte JC, Dehayem MY, Deshmukh S, Squires S, Shields BM, Hattersley AT, McDonald TJ, Nyirenda M, Sobngwi E, Jones AG, et al (2023). Most young people diagnosed with type 1 diabetes in Cameroon and Uganda have diabetes that is unlikely to be autoimmune origin: Evidence from Young-Onset Diabetes in sub-Saharan Africa (YODA) study.  Author URL.
Young KG, McGovern AP, Hopkins R, Raya D, Pearson ER, Hattersley AT, Jones AG, Shields BM, Dennis JM (2023). Precision medicine in type 2 diabetes: Individual-level prediction of heart failure risk accurately identifies people most likely to benefit with SGLT2-inhibitors.  Author URL.
Cardoso P, Young KG, Hopkins R, Raya D, Jones AG, Pearson ER, Hattersley AT, Shields BM, McKinley TJ, Dennis JM, et al (2023). Precision medicine in type 2 diabetes: Simple clinical characteristics alter the glucose-lowering efficacy of SGLT2-inhibitors and GLP-1 receptor agonists and can determine optimal therapy choice.  Author URL.
Dennis JM, Young K, Cardoso P, Hopkins R, Pearson E, Hattersley A, McKinley T, Jones A, Shields BM (2023). Precision medicine in type 2 diabetes: validation of an treatment selection model for SGLT2-inhibitor and DPP4-inhibitor therapies in people of non-white ethnicity.  Author URL.
de Villiers E, Hill A, Fraser D, Bolt R, McDonald T, Shield B, Jones A (2023). Prediction models for diabetes classification can identify patients treated as having type 2 diabetes who progress to insulin therapy within three years.  Author URL.
Thomas NJM, Hill AV, Shields BM, McDonald TJ, Patel K, Jones AG (2023). Progressive loss of insulin secretion in adult-onset type 1 diabetes is not impacted by clinical features or genetic predisposition to type 1 diabetes.  Author URL.
Chakka S, Thomas NJ, Fraser D, Hattersley A, Patel K, Jones AG (2023). Severe endogenous insulin deficiency is rare in long standing type 2 diabetes and usually reflects misclassified autoimmune aetiology diabetes.  Author URL.
Chakka S, Thomas NJ, Fraser D, Hattersley AT, Patel K, Jones AG (2023). Severe endogenous insulin deficiency is rare in longstanding type 2 diabetes and usually reflects misclassified autoimmune aetiology diabetes.  Author URL.
Hopkins R, Young KG, Thomas NJ, Jones AG, Hattersley AT, Shields BM, Dennis JM, McGovern AP (2023). Treatment outcomes with oral anti-hyperglycaemic therapy for people with diabetes secondary to chronic pancreatitis: matched population based cohort study.  Author URL.
JONES A, SHIELDS B, ORAM RA, DABELEA D, HAGOPIAN W, LUSTIGOVA E, SHAH AS, MOTTL AK, DAGOSTINO R, WILLIAMS AH, et al (2022). 985-P: Prediction Models Combining Clinical Measures Identify Participants with Youth-Onset Diabetes Who Maintain Insulin Secretion.
Thomas N, Hill A, Bolt R, Tippett P, Shields B, McDonald T, Jones A (2022). Age of onset does not affect progression of robustly defined adult onset type 1 diabetes.  Author URL.
Simpson V, Thomas N, Hill AV, Shields BM, Deshmukh S, McDonald TJ, Jones AG (2022). Antibody positive patients with type 2 diabetes who rapidly progress to insulin have similar characteristics and type 1 genetic risk scores as patients with type 1 diabetes.  Author URL.
Katte JC, Sobngwi E, Dehayem MY, Deshmukh S, Patel K, Shields B, Hattersley AT, McDonald TJ, Jones AG (2022). Evidence of atypical non-autoimmune diabetes amongst young people diagnosed with type 1 diabetes in Cameroon: results from young-onset diabetes in sub-Saharan Africa study.  Author URL.
Grace SL, Long AE, Gillespie KM, Williams AJK, Lampasona V, Achenbach P, Pearson ER, McDonald TJ, Jones AG (2022). Glutamate decarboxylase autoantibody characteristics can stratify those at risk of early insulin requirement in adult-onset type 2 diabetes.  Author URL.
Brackley SM, Thomas N, Hill A, Shields B, Fox C, McDonald T, Huber J, Jones AG (2022). In adults with new onset type 1 diabetes baseline psychological resilience is prospectively associated with HbA1c.  Author URL.
Simpson VE, Thomas N, Hill AV, Deshmukh S, Shields BM, McDonald T, Jones AG (2022). In people with suspected type 1 diabetes or rapid progression to insulin, a single positive islet autoantibody confirms the genetic characteristics and progression of classical type 1 diabetes.  Author URL.
Shields B, Angwin C, Jones AG, Holman RR, Sattar N, Britten N, Pearson E, Shepherd M, Hattersley AT (2022). Let the patient choose! Patient preferences for type 2 diabetes therapy in the trimaster double-blind three-way randomised crossover trial.  Author URL.
Young KG, McGovern AP, Hopkins R, Raya D, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Shields BM, et al (2022). Precision medicine in type 2 diabetes: integrating trial and real-world evidence can provide accurate estimates of heart failure benefit when initiating SGLT2-inhibitors.  Author URL.
Thomas N, Hill A, Bolt R, Tippett P, Shields B, McDonald T, Jones A (2022). Progression of robustly defined adult onset type 1 diabetes is unaffected by onset age suggesting their inclusion in intervention studies is possible.  Author URL.
Brackley SM, Thomas N, Hill A, Shields B, McDonald T, Fox C, Huber J, Jones A (2022). Psychological resilience is predictive of future HbA<sub>1c</sub> and mental health status in adults with new onset type 1 diabetes.  Author URL.
Angwin CD, Shields BM, Jones AG, Pearson ER, Hattersley AT (2022). Raised levels of brain natriuretic peptide (BNP) in patients with type 2 diabetes but no known heart failure are rare and not associated with improved response to SGLT2 inhibitors: Findings from the TriMaster study.  Author URL.
Brackley SM, Thomas N, Carr A, Andrews R, Hope SV, Jones AG (2022). Random c-peptide is a pragmatic measure of beta cell function, predicting glucose variability and hypoglycaemia risk.  Author URL.
Grace SL, Long AE, Gillespie KM, Williams AJK, Lampasona V, Achenbach P, Pearson ER, McDonald TJ, Jones AG (2022). Rapid insulin progression in glutamate decarboxylase autoantibody positive adult-onset diabetes can be better predicted by detecting autoantibodies to n-terminally truncated GAD(96-585).  Author URL.
Eason RJ, Thomas NJ, Hill AV, Deshmukh S, Hattersley AT, Shields BM, McDonald TJ, Jones AG (2022). Routine islet autoantibody testing in newly diagnosed adult-onset type 1 diabetes can guide clinical reclassification and successful insulin cessation.  Author URL.
Ferrat L, Carr A, Vehik K, Setck A, Patel K, Jones AJ, Krischer J, Hagopian W, Redondo M, Oram R, et al (2022). TYPE 1 DIABETES RISK CALCULATOR FOR CLINICAL RESEARCHERS AND CLINICIANS.  Author URL.
Katte JC, Sobngwi E, Dehayem MY, Deshmukh S, Patel KA, Shields BM, McDonald TJ, Jones AG (2022). The majority of young people diagnosed with type 1 diabetes in Cameroon do not have evidence of islet autoimmunity: Results from the Young-Onset Diabetes in sub-Saharan Africa (YODA) study.  Author URL.
Tecklenborg J, Thomas NJ, Jones AG, Oram RA (2021). A type 1 diabetes diagnostic model including type 1 diabetes genetic risk score and clinical features aids in classification of adult patients with clinical type 1 diabetes that are islet autoantibody negative.  Author URL.
Green HD, Thomas NJ, Tyrrell J, Jones A, Evans JP, Smith C, Oram RA, Jones AG, Weedon MN (2021). Genetic analysis confirms type 1 diabetes is a cause of multiple musculoskeletal conditions.  Author URL.
Young KG, Dennis JM, Thomas NJ, Jones AG, McGovern A, Shields BM, Barroso I, Hattersley AT (2021). Participants with undiagnosed diabetes in UK Biobank wait on average two years to receive a diagnosis, and simple clinical features are associated with diagnosis delays.  Author URL.
Eason R, Hill A, Shields B, Tippett P, McDonald T, Hattersley A, Oram R, Knight B, Thomas N, Jones A, et al (2021). The absence of islet autoantibodies when routinely tested in adult-onset type 1 diabetes is associated with a high prevalence of treatment change and successful insulin cessation.  Author URL.
Tippett PW, Hill AV, Bolt R, Lynam AL, Carr ALJ, Hattersley AT, McDonald TJ, Oram RA, Shields BM, Jones AG, et al (2020). A clinical prediction model combining clinical features and type 1 diabetes genetic risk has high accuracy for classification of adult onset diabetes at diagnosis.  Author URL.
Carr ALJ, Sharp SA, Young KG, Thomas NJ, Hattersley AT, Jones AG, Oram RA (2020). A type 1 diabetes genetic risk score is discriminative of adult-onset type 1 diabetes.  Author URL.
(2020). Clinical care and other categories posters: Type 1 diabetes.
Dennis JM, Donnelly LA, Henley WE, Jones AG, McGovern AP, Sattar N, Holman RR, Pearson ER, Hattersley AT, Shields BM, et al (2020). Development of a decision aid for primary care to predict the best glucose-lowering treatment after metformin for people with type 2 diabetes.  Author URL.
Young KG, Thomas NJ, Jones AG, McGovern A, Shields BM, Barroso I, Hattersley AT (2020). HbA<sub>1c</sub> screening in 195,460 'non-diabetic' individuals (40-69 years) identifies 1.1% with undiagnosed diabetes 2 years before clinical diagnosis.  Author URL.
Greiner RS, Hill A, Knight BA, McDonald T, Shields B, Jones AG, Rodgers LR (2020). HbA<sub>1c</sub> thresholds have substantial impact in screening procedures for those at risk of developing type 2 diabetes.  Author URL.
Thomas N, Hill A, Tippett P, McDonald T, Knight B, Carr A, Oram R, Hattersley A, Weedon M, Jones A, et al (2020). Patterns of autoimmunity of genetically defined adult onset type 1 diabetes are different above and below 30 years of age, without impacting on clinical presentation.  Author URL.
Greiner R, Hill A, Knight BA, McDonald T, Shields BM, Jones AG, Rodgers L (2020). Performance and implications of NICE-recommended screening for identifying those at risk of type 2 diabetes: Results from a UK population cohort.  Author URL.
Grace SL, Cooper A, Jones AG, McDonald TJ (2020). Zinc transporter 8 autoantibody testing requires age-specific cut-offs.  Author URL.
Deshmukh HA, Madsen AL, Have C, Mahajan A, Frayling T, Franks P, Pearson A, Mari A, Hansen T, Walker M, et al (2019). A Genome-Wide Association (GWAS) meta-analysis of pancreatic beta cell glucose sensitivity.  Author URL.
Bizzotto R, Jennison C, Jones A, Walker M, Pearson ER, Mari A (2019). Glucose sensitivity, insulin sensitivity and their longitudinal changes are strong independent determinants of type 2 diabetes progression: an IMI DIRECT study.  Author URL.
Shields B, McDonald T, Owen K, Malecki M, Jones A, Colclough K, Hattersley A (2019). Improving the MODY calculator for use in insulin treated patients with the addition of C-peptide and islet autoantibodies.  Author URL.
Hill AV, Tippett P, McDonald TJ, Knight BA, Hattersley AT, Jones AG (2019). No single clinical feature can robustly classify diabetes at diagnosis, but approaches that integrate clinical features have high diagnostic accuracy.  Author URL.
Dennis JM, Henley W, Jones A, McGovern A, Pearson E, Hattersley A, Shields B (2019). Precision medicine in type 2 diabetes: harnessing individual-level trial data alongside routine care records to identify predictors of response to SGLT2 inhibitors and DPP4 inhibitors.  Author URL.
Jones AG, Hill AV, Trippett PW, Hattersley AT, McDonald TJ, Shields BM (2019). The utility of clinical features and glycaemia at diagnosis in classifying young adult onset diabetes.  Author URL.
Rodgers LR, Hill AV, Hattersley AT, McDonald TJ, Jones A, Shields BM (2019). Time to revise HbA<sub>1c</sub> thresholds for diabetes risk? Evidence from a prospective study of 4010 participants.  Author URL.
Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019). Using trial data to test the proposed 5 novel subgroups of diabetes from Ahlqvist et al. derived from cluster analysis: simple clinical measures markedly outperform the 5 subgroups to predict drug response and diabetes progression.  Author URL.
Niwaha A, Nakanga W, Katte J-C, Shields B, Jones A, Nyirenda M, McDonald T (2019). When there is no haemolysis, plasma C-peptide levels are stable up to 5 days at 4°C.  Author URL.
Grubb AL, Donnelly LA, Slieker RC, McDonald TJ, Rutters F, 't Hart LM, Pearson ER, Hattersley AT, Shields BM, Jones AG, et al (2018). A Type 1 diabetes genetic risk score can identify patients with glutamic acid decarboxylase (GAD) antibody-positive Type 2 diabetes with and without rapid progression to insulin therapy.  Author URL.
Dennis JM, Henley WE, Weedon MN, Rodgers LR, Jones AG, Pearson ER, Hattersley AT, Shields BM (2018). Are the new drugs better? Changing UK prescribing of Type 2 diabetes medications and effects on HbA1c and weight, 2010 to 2016.  Author URL.
Grubb AL, Patel K, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Owen KR, Shields BM, et al (2018). Development and validation of a clinical prediction model to identify adult patients (aged 18-50) with type 1 diabetes requiring early insulin therapy.  Author URL.
McGovern A, Dennis J, Shields B, Pearson E, Hattersley A, Jones A (2018). HbA<sub>1c</sub> is highly variable in people with type 2 diabetes on stable therapy in both trial and real-world settings: implications for clinical practice.  Author URL.
Kimmitt RA, Dennis JM, Weedon M, Rodgers LR, Jones AG, Pearson ER, Hattersley AT, Oram RA, Shields BM (2018). Higher estimated glomerular filtration rate (eGFR) is associated with improved glycaemic response to sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with Type 2 diabetes and normal renal function: a MASTERMIND study.  Author URL.
Garbutt JDW, England C, Papadaki A, Andrews RC, Jones AG, Johnson L (2018). Is adherence to a Mediterranean diet associated with progression of Type 2 diabetes?.  Author URL.
Mcgovern AP, Rogers L, Weedon M, Shields B, Pearson E, Hattersley AT, Jones A (2018). Is there benefit from continuing glucose lowering therapies which have a poor initial response in Type 2 diabetes?.  Author URL.
Shakweh EY, Shields BM, Angwin CD, Rodgers LR, McDonald TJ, Pearson ER, Hattersley AT, Jones AG (2018). Precision medicine in Type 2 diabetes: is variation in response to sitagliptin and gliclazide therapy related to drug levels?.  Author URL.
Marren SM, Hammersley S, Knight B, Bolt R, Hill A, Hattersley AT, McDonald TJ, Jones AG, Oram RA (2018). Preserved beta cell function in long-duration Type 1 diabetes is associated with markedly lower hypoglycaemia and insulin dose but no improvements in HbA1c, suggesting the need to intensify therapy.  Author URL.
Tippett PW, Hill AV, McDonald TJ, Hattersley AT, Jones AG (2018). Prevalence and clinical associations of ZnT8 islet autoantibodies in the first year of adult diabetes.  Author URL.
Oram RA, Hammersley S, Knight BA, Bolt R, Hill A, Jones AG, Hattersley AT, McDonald TJ (2018). Proinsulin measurement suggests persistent beta cells even in those with undetectable c-peptide in long-duration Type 1 diabetes: Evidence for disordered insulin processing.  Author URL.
Huber JW, Fox C, Hill A, McDonald T, Shields B, Jones A (2018). Psychological resilience in Type 1 diabetes carries independent benefits for blood glucose control.  Author URL.
Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2018). Trial data show the proposed 5 diabetes subgroups from cluster analysis do predict drug response and diabetes progression but simple clinical measures are stronger predictors.  Author URL.
Grubb AL, Patel KA, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Shields BV, Jones AG, et al (2017). Development of a risk calculator to identify patients with Type 1 diabetes who will require early insulin therapy.  Author URL.
Hope SV, Knight BA, Shields BM, Hill A, Choudhary P, Strain WD, Hattersley AT, McDonald TJ, Jones G (2017). RANDOM NON-FASTING C-PEPTIDE CAN BE USED AS a RISK ASSESSMENT TOOL FOR HYPOGLYCAEMIA IN ELDERLY NSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES.  Author URL.
Patel KA, Hill A, Shields BM, Oram RA, Jones A, Hattersley AT (2017). Type 2 diabetes and severe insulin deficiency.  Author URL.
Dawed AY, Jones AG, McDonald TJ, Walker M, Mari A, Franks PW, Pearson ER (2016). Determinants of glucagon secretion in prediabetes and recently diagnosed type 2 diabetes: an IMI-DIRECT study.  Author URL.
Hope SV, Knight BA, Shields BM, Strain WD, Hattersley AT, Choudhary P, Jones AG (2016). Low c-peptide is associated with high glycaemic variability and hypoglycaemia in insulin-treated patients with Type 2 diabetes.  Author URL.
Shields BM, Dennis JM, Henley W, Weedon M, Lonergan M, Rodgers L, Jones AG, Holman RR, Pearson ER, Hattersley AT, et al (2016). Personalising therapy in type 2 diabetes: the effect of BMI and sex on glycaemic response and side effects to sulphonylureas and thiazolidinediones.  Author URL.
Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Holman RR, Pearson ER, Hattersley AT, Shields BM, et al (2016). Personalizing Therapy in Type 2 Diabetes: the Effect of BMI and Gender on Response and Side Effects to Sulfonylureas and Thiazolidinediones.  Author URL.
Hope SV, Knight BA, Shields BM, Hattersley AT, McDonald TJ, Jones AG (2016). Random non-fasting c-peptide provides an accurate measure of endogenous insulin secretion for clinical practice.  Author URL.
Dennis JM, Hattersley AT, Henley WE, Jones AG, Pearson ER, Shields BM (2016). Stratification using gender and body mass index (BMI) can predict side-effect risk in people with Type 2 diabetes initiating thiazolidinediones but not sulphonylureas: a MASTERMIND study.  Author URL.
Craig ZV, Hill AV, McDonald TJ, Hattersley AT, Jones AG, Shields BM (2016). Time to change the HbA1c cut-off for prediabetes.  Author URL.
Oram RA, Hill A, Mcdonald TJ, Patel KA, Jones AG, Hattersley AT, Weedon MN (2015). A Novel, Inexpensive Test can Discriminate between Type 1 and Type 2 Diabetes.  Author URL.
Weedon MN, Hill AV, McDonald TJ, Patel KA, Jones A, Hattersley AT, Oram R (2015). A novel inexpensive test can discriminate between Type 1 and Type 2 diabetes.  Author URL.
Jones AG, Lonergan M, Rodgers LR, Henley WE, Pearson EW, Hattersley AT, Shields BM (2015). Studies of diabetes treatment stratification should correct for baseline HbA1c: a MASTERMIND study.  Author URL.
Jones AG, McDonald TJ, Hill AV, Stewart J, Shields BM, Knight BA, Hattersley AT (2014). Markers of beta cell failure are associated with reduced glycaemic response to GLP-1 agonists in Type 2 diabetes.  Author URL.
Jones AG, Hill AV, Stewart J, Githens-Mazer G, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2013). Baseline HbA1c is the major clinical predictor of glycaemic response to incretin based agents in Type 2 diabetes.  Author URL.
Knight BA, Shields BM, Baker GC, Hattersley AT, Jones AG (2013). Effectiveness of screening questionnaires to detect HbA1c defined abnormal glycaemia in a UK White population.  Author URL.
Oram RA, McDonald TJ, Jones AG, Besser REJ, Hattersley AT (2013). The majority of patients with over five years of Type 1 diabetes are insulin microsecretors and have functioning beta cells.  Author URL.
Hope SV, Jones AG, Shepherd M, Shields B, Strain D, McDonald T, Knight BA, Hattersley AT (2013). Urinary C-peptide creatinine ratio to detect absolute insulin deficiency in type 2 diabetes.  Author URL.
Knight BA, Shields B, Baker G, Hattersley A, Jones A (2012). Screening questionnaires are useful in identifying undiagnosed HbA<sub>1c</sub> diagnosed diabetes in a Caucasian population.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Shields BM, Hope SV, Bowman PA, Oram RA, Knight BA, Hattersley AT (2011). Measuring endogenous insulin secretion: does it matter in insulin treated patients?. Diabetes UK Annual Professional Conference 2011. 30th Mar - 1st Apr 2011.
Jones AG, Besser REJ, Shields BM, McDonald TJ, Hope SV, Oram RA, Knight BA, Hattersley AT (2011). Practical alternatives to the mixed meal tolerance test in insulin treated diabetes. Diabetes UK Annual Professional Conference 2011. 30th Mar - 1st Apr 2011.
Thomas NJM, Besser REJ, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011). Simple and convenient alternatives to the mixed meal tolerance test.  Author URL.
Hope SV, Jones A, Goodchild E, Shepherd M, Besser REJ, Shields B, McDonald T, Knight BA, Hattersley A (2011). URINARY C-PEPTIDE CREATININE RATIO (UCPCR) CAN BE USED AS a SCREENING TOOL TO DETECT ABSOLUTE INSULIN DEFICIENCY IN PEOPLE WITH TYPE 2 DIABETES.  Author URL.
Hope SV, Jones AG, Goodchild E, Shepherd M, Besser REJ, Shields BM, McDonald TJ, Knight BA, Hattersley AT (2011). Urinary C-Peptide Creatinine Ratio (UCPCR) can be used as a screening tool to detect absolute insulin deficiency in type 2 diabetes. Diabetes UK Annual Professional Conference 2011. 30th Mar - 1st Apr 2011.
Shields BM, Shepherd MH, McDonald T, Besser REJ, Jones AG, Raju NB, Wensley KJ, Githens-Mazer G, Knight BA, Hattersley AT, et al (2010). Clinical Criteria Are Poor at Identifying Type 1 Diabetes. Should We be Measuring Insulin Deficiency Directly?.  Author URL.
Jones AG, Hope SV, Shepherd M, Shields BM, Besser REJ, Wensley KJ, Githens-Mazer G, McDonald TJ, Knight BA, Hattersley AT, et al (2010). Do patients with Long-Standing Type 2 Diabetes Develop Absolute Insulin Deficiency?.  Author URL.
Jones AG, Besser REJ, McDonald TJ, Wensley KJ, Githens-Mazer G, Shields BM, Knight BA, Hattersley AT (2010). Serum Measurement of Endogenous C-Peptide after a Mixed Meal can be Replaced with a Single Post Meal Urine C-Peptide Creatinine Ratio (UCPCR).  Author URL.
Shields BM, McDonald TJ, Bowman P, Jones AG, Besser REJ, Wensley KJ, Githens-Mazer G, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio (UCPCR) is a Reliable Measure of Endogenous Insulin Secretion, Even in Patients with Renal Impairment.  Author URL.
Besser REJ, Jones AG, McDonald TJ, Shields BM, Githens-Mazer G, Wensley K, Knight BA, Hattersley AT (2010). Urinary C-Peptide Creatinine Ratio is a Novel Non Invasive Alternative to the Inpatient Mixed Meal Tolerance Test in Young Onset Type 1 Diabetes.  Author URL.

Back to top

Edit Profile